- Home
- VANI
as 05-30-2025 4:00pm EST
Vivani Medical Inc is a preclinical-stage biopharmaceutical company. The company develops miniaturized, subdermal implants utilizing its proprietary NanoPortal technology to enable long-term, near-constant-rate delivery of a broad range of medicines to treat chronic diseases. It has two reporting segments, the Biopharm Division and the Neuromodulation Division. The Biopharm Division includes activities from NPM and Vivani Medical Australia Pty Ltd, and the Neurostimulation Division includes activities from Cortigent and its subsidiary in Switzerland.
| Founded: | 1998 | Country: | United States |
| Employees: | N/A | City: | ALAMEDA |
| Market Cap: | 68.1M | IPO Year: | 2014 |
| Target Price: | $4.00 | AVG Volume (30 days): | 66.4K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 1 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -0.42 | EPS Growth: | N/A |
| 52 Week Low/High: | $0.91 - $2.09 | Next Earning Date: | 05-13-2025 |
| Revenue: | N/A | Revenue Growth: | N/A |
| Revenue Growth (this year): | N/A | Revenue Growth (next year): | N/A |
Stock Insider Trading Activity of Vivani Medical Inc. (DE) (VANI)
| Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Williams Gregg | VANI | Director10% Owner | May 14 '25 | Buy | $1.01 | 12,740 | $12,867.40 | 13,840,895 | |
| Williams Gregg | VANI | Director10% Owner | Apr 24 '25 | Buy | $1.01 | 1,113 | $1,124.13 | 13,840,895 | |
| Williams Gregg | VANI | Director10% Owner | Apr 21 '25 | Buy | $1.01 | 1,812 | $1,830.12 | 13,840,895 | |
| Williams Gregg | VANI | Director10% Owner | Apr 9 '25 | Buy | $1.02 | 20,840 | $21,233.69 | 13,840,895 | |
| Williams Gregg | VANI | Director10% Owner | Apr 4 '25 | Buy | $0.99 | 205,482 | $205,258.15 | 13,840,895 | |
| Williams Gregg | VANI | Director10% Owner | Apr 2 '25 | Buy | $1.01 | 24,939 | $24,959.00 | 13,840,895 | |
| Dwyer Donald | VANI | Chief Business Officer | Apr 1 '25 | Buy | $1.03 | 4,000 | $4,100.00 | 55,000 |
Latest Vivani Medical Inc. (DE) News
VANI Breaking Stock News: Dive into VANI Ticker-Specific Updates for Smart Investing
GlobeNewswire
2 days ago
Vivani Medical Announces Filing of Form 10 Registration Statement for Planned Spin-Off of Cortigent Neurostimulation Business to Vivani Shareholders
Associated Press Finance
18 days ago
Vivani Medical: Q1 Earnings Snapshot
GlobeNewswire
18 days ago
Vivani Medical Provides Business Update Including $3M Equity Financing and Reports First Quarter 2025 Financial Results
GlobeNewswire
24 days ago
Vivani Medical to Present at the American Association of Pharmaceutical Scientists’ “Beyond GLP1s: Where the Science will Take Business Next” Virtual Workshop
GlobeNewswire
a month ago
Vivani Medical to Participate in Virtual Fireside Chat Hosted by H.C. Wainwright & Company
MT Newswires
2 months ago
Vivani Medical, Okava Expand Weight-Loss Drug Collaboration to Include Dogs
GlobeNewswire
2 months ago
Vivani Medical and Okava Expand Collaboration to Develop OKV-119 for Dogs, Targeting Metabolic Health and Longevity
Benzinga
2 months ago
EXCLUSIVE: Vivani Medical Collaborates With Okava To Expand Development Of GLP-1 Therapy For Dogs
Compare VANI vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "VANI Vivani Medical Inc. (DE) - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.